Īrija -
angļu -
HPRA (Health Products Regulatory Authority)
dopacard 10 micromol concentrate for soln for inf
cephalon limited - dopexamine hydrochloride - concentrate for soln for inf - 10 micromol
Jaunzēlande -
angļu -
Medsafe (Medicines Safety Authority)
dopacard
new zealand medical & scientific ltd - dopexamine hydrochloride 1%; - solution for injection - 1 % - active: dopexamine hydrochloride 1% excipient: disodium edetate dihydrate hydrochloric acid water for injection
Lielbritānija -
angļu -
MHRA (Medicines & Healthcare Products Regulatory Agency)
dopacard 50mg/5ml concentrate for solution for infusion ampoules
teva uk ltd - dopexamine hydrochloride - solution for infusion - 10mg/1ml
Īrija -
angļu -
HPRA (Health Products Regulatory Authority)
dopacard concentrate for soln for inf 10
cephalon limited - dopexamine hydrochloride - concentrate for soln for inf - 10
Īrija -
angļu -
HPRA (Health Products Regulatory Authority)
dopacard 200 milligram
ipsen limited - dopexamine hydrochloride - 200 milligram
Īrija -
angļu -
HPRA (Health Products Regulatory Authority)
dopacard 50 milligram
ipsen limited - dopexamine hydrochloride - 50 milligram
Lielbritānija -
angļu -
MHRA (Medicines & Healthcare Products Regulatory Agency)
dopamine 200mg/5ml solution for infusion ampoules
martindale pharmaceuticals ltd - dopamine hydrochloride - solution for infusion - 40mg/1ml
Tanzānija -
angļu -
Tanzania Medicinces & Medical Devices Authority
pifeltro 100 mg film-coated tablet film coated tablet
msd (pty) limited, south africa - dopexamine - film coated tablet - 100
Lielbritānija -
angļu -
MHRA (Medicines & Healthcare Products Regulatory Agency)
dopamine 800mg/5ml solution for infusion ampoules
martindale pharmaceuticals ltd - dopamine hydrochloride - solution for infusion - 160mg/1ml
Eiropas Savienība -
angļu -
EMA (European Medicines Agency)
ongentys
bial - portela cª, s.a. - opicapone - parkinson disease - anti-parkinson drugs - ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.ongentys is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.